SUMMARY
Approximately 600 primary total hip and 550 primary knee replacements are performed at the Avon Orthopaedic Centre each year, commonly with a combination of subarachnoid block and general anaesthesia. Early hypotension is usually effectively treated with intravenous fluid boluses and increments of vasoconstrictor drugs. However, in the following three cases, hypotension was considerably more severe than usual and refractory to treatment.
CASE 1
A 68-year-old woman presented for total hip replacement. She was moderately obese, weight 96 kg, with a history of hypertension controlled by oral lisinopril 40 mg, nifedipine 20 mg and amiloride 5 mg, all continued on the day of surgery. Her admission blood pressure was 188/100. An anaesthetic thirty years previously had been uneventful. She had no known allergies.
She was given premedication of temazepam 20 mg, ranitidine 150 mg and metoclopramide 10 mg, all orally. After routine monitoring was instituted with ECG, pulse oximetry and non-invasive blood pressure, and an intravenous infusion of Hartmann's solution 1.0 litre started, a spinal anaesthetic was performed using plain bupivacaine 0.5% 3.5 ml. The patient was then anaesthetized with fentanyl 100 µg, propofol 100 mg and atracurium 40 mg IV. After tracheal intubation, positive pressure ventilation with oxygen, nitrous oxide and isoflurane 0.3%-1.0% was started. The patient was placed in the right lateral position for surgery, and cephamandole 1g IV antibiotic prophylaxis given.
Early hypotension (105/50 mmHg) during the first 30 minutes after induction was treated with continued intravenous fluid loading with Hartmann's solution 1.0 litre and ephedrine 6 mg increments IV. Approximately 55 minutes after induction, and about five minutes after Gelofusin infusion was started, the patient developed sudden and profound hypotension (systolic 45 mmHg). Immediately prior to this the pulse rate had been stable at 80 to 90 beats per minute. The pulse increased moderately to 110 bpm with the onset of hypotension and administration of intravenous ephedrine. There was no response to further intravenous ephedrine (30 mg total dose), methoxamine (10 mg total dose) and rapid infusion of a further 1.0 litre of Gelofusin intravenously, and the patient remained profoundly hypotensive. The capnograph trace, having previously been normal, showed a rising plateau suggesting bronchospasm, and the patient's face became markedly oedematous. Suspecting an anaphylactoid reaction, Gelofusin was stopped and adrenaline 100 µg increments were given intravenously with good effect. The period of instability lasted about 20 minutes. Surgery was abandoned to allow resuscitation and repositioning of the patient for insertion of a central venous line. No bone cement had been used and blood loss was 800 ml. A total of crystalloid 6l, Gelofusin 2l, human albumin solution 4.5% 500 ml and two units of blood was infused to maintain the central venous pressure. There was increased oozing from the hip wound. Clotting studies confirmed disseminated intravascular coagulation. (Prothrombin time 104 s (normal range 9-15 s); activated partial thromboplastin time >180 s (27-35 s); fibrin degradation products >8 mg/l (0.01-0.50 mg/l).)
Postoperatively she was transferred to the intensive care unit and required an intravenous infusion of adrenaline for 24 hours. Her coagulation studies returned to normal over a few hours, and she made a full recovery in the following 48 hours.
Because we suspected an anaphylactoid reaction, immunological studies were performed. Mast cell tryptase (at 2 and 4 hours) was undetectable (normal range <0.5 µg/litre). Skin tests for propofol, atracurium, fentanyl, cephamandole and Gelofusine and RAST latex tests were all negative. Complement C3 and C4 were in the normal range.
CASE 2
A 74-year-old woman presented for total knee replacement. She had mild asthma and used a salbutamol inhaler occasionally. She had hypertension controlled by oral enalapril 5 mg and bendrofluazide 2.5 mg, both taken preoperatively on the day of surgery. Her admission blood pressure was 160/90 mmHg. She had no known allergies and had undergone an uneventful total hip replacement in 1988. She was not taking an ACE inhibitor at that time.
After premedication with oral temazepam 20 mg, she was fully monitored and an intravenous infusion of Hartmann's solution started. General anaesthesia was induced intravenously with fentanyl 75 µg and propofol 100 mg. A laryngeal mask was inserted and she continued to breathe spontaneously on oxygen, nitrous oxide and isoflurane 0.5 to 1%. Spinal anaesthesia was performed using plain bupivacaine 0.5% 3.5 ml.
Hypotension (systolic 95 mmHg) during the first 45 minutes was controlled with intravenous ephedrine 30 mg and fluid loading with Hartmann's solution 1.0l and Gelofusin 500 ml. Surgery was begun after a tourniquet was inflated on the affected leg. An hour after induction, the patient suddenly became profoundly hypotensive with a measured systolic of 40 mmHg. Her pulse remained at approximately 75 bpm prior to and after hypotension occurred. There was no apparent cause; bone cement had not yet been used, the tourniquet was still inflated and blood loss was minimal. The hypotension was extremely refractory to intravenous methoxamine increments (20 mg total dose), more ephedrine (18 mg total dose) and intravenous phenylephrine 200 µg boluses. After phenylephrine 1.4 mg, the blood pressure was finally restored. Surgery was completed successfully.
After a prolonged stay in the recovery ward with further haemodynamic instability, she was maintained on a dobutamine infusion for three days and finally made a complete recovery. Anaphylaxis was not suspected, and therefore no specific tests performed.
CASE 3
A 73-year-old woman weighing 53 kg presented for total hip replacement. She was in good general health with no known allergies and no history of previous anaesthetic problems. Long-standing hypertension was controlled by oral lisinopril 10 mg taken preoperatively on the day of surgery. Her admission blood pressure was 160/100 mmHg. She was premedicated with oral temazepam 20 mg and metoclopramide 10 mg. After applying standard monitoring (blood pressure 120/55 mmHg), anaesthesia was induced intravenously with fentanyl 75µg and propofol 100 mg and maintained with oxygen, nitrous oxide and isoflurane 0.5 to 1%, the patient breathing spontaneously through a laryngeal mask airway. Spinal anaesthesia was performed with plain bupivacaine 0.5% 3 ml.
Hypotension (80/40 mmHg) ten minutes after induction was promptly treated with continued intravenous fluid loading with Hartmann's solution and intravenous increments of ephedrine 3 mg. About 35 minutes after the spinal block was administered and shortly after commencing Gelofusin infusion, profound hypotension suddenly occurred (systolic 60 mmHg), with a stable pulse rate of 60 bpm. Further fluid loading, intravenous ephedrine and methoxamine had little effect. The capnograph showed a rising plateau, consistent with bronchospasm. After the experience of Case 1, intravenous adrenaline (50 µg increments) was given early with good effect. Bone cement was not used until after this episode, acetabular cementing at 65 minutes and femoral cementing at 90 minutes after performing the spinal anaesthetic.
Towards the end of surgery, further fluid volume was required to replace blood loss. Gelofusin infusion was restarted as it was not clear that previous hypotension had been related to Gelofusin administration. However, the patient again became profoundly hypotensive, which responded to further intravenous adrenaline and discontinuation of the Gelofusin infusion. A total of Hartmann's solution 2.0l and Gelofusin 1.9l was given. Blood loss was 450 ml. Postoperatively the patient had marked facial oedema.
Immunological follow-up was arranged because we suspected an anaphylactoid reaction. Mast cell tryptase, taken acutely at 1 and 4 hours was undetectable. Skin testing (fentanyl, cefamandole, propofol and Gelofusin) at six weeks was negative. However, a fall in C3 to 0.45 g/l (normal range 0.8-1.6 g/l), returning to normal at 24 hours, with normal C4 levels throughout, suggested the possibility of transient alternate pathway activation. Again the patient made a full recovery.
DISCUSSION
We have seen three cases of profound hypotension which were unusually resistant to treatment with fluids and vasoconstrictors. In two cases, where there was hypotension, oedema and bronchospasm, we suspected an anaphylactoid reaction. However, immunological testing with both serial acute mast cell tryptase assay and skin testing at six weeks did not confirm this. Other explanations for severe hypotension include sympathetic blockade, use of bone cement, blood loss, tourniquet release or cardiovascular event. However, the sequence of events, clinical presentation and refractoriness to treatment in these cases are not readily explained by the above causes. All the patients were taking angiotensin converting enzyme inhibitors (ACEIs) preoperatively, which they had taken on the day of surgery. Profound hypotension in association with ACEIs has been reported in journals of cardiovascular anaesthesia, but not in the more general literature.
Angiotensin-converting enzyme (ACE) is a carboxypeptidase which converts angiotensin I to the active angiotensin II. It is widely distributed throughout the body but mainly membrane-bound on the luminal aspect of vascular endothelial cells. The soluble form circulating in plasma has relatively little activity. Plasma ACE levels vary widely between individuals and this variability is largely genetically determined 1 . ACE also metabolizes bradykinin 2 . Bradykinin is a potent autacoid which stimulates the release of mediators, including nitric oxide, thus relaxing vascular smooth muscle cells 3, 4 . It also induces the release of vasodilating prostaglandins [3] [4] . It has a very short plasma half-life, being rapidly degraded by ACE, which limits its action to local tissue level. Bradykinin has little systemic effect unless ACE is inhibited. ACEIs block the action of membranebound ACE, inhibiting the conversion of angiotensin I to angiotensin II, and also inhibit the degradation of bradykinin; both actions thus cause hypotension 4 . Gelofusin is a synthetic colloid solution of 4% succinylated gelatine in saline with a mean molecular weight of 35,000. In severe reactions to Gelofusin and other substituted gelatine solutions, there are high plasma levels of vasoactive substances (data sheet, Braun Medical Ltd.), although the origin of these substances is unclear. This may explain why, in our cases, Gelofusin seemed to make matters worse. The Committee on Safety of Medicines (U.K.) reports no other putative cases of an interaction between Gelofusin and ACEIs.
ACEIs are associated with profound hypotensive responses. Intravenous injection of bradykinin in volunteers caused dose-dependent hypotension, potentiated twenty-to fifty-fold by pretreatment with ACEIs 2 . Bradykinin prevents vasoconstriction mediated by noradrenaline which may explain why indirect acting vasopressors such as ephedrine were ineffective in this circumstance 2 . Patients receiving ACEIs and undergoing therapeutic plasma exchange with human albumin replacement solutions often have atypical reactions characterized by flushing, hypotension, dyspnoea and bradycardia 5 . Albumin solutions contain low levels of prekallikrein activating factor (Hageman Factor), a bradykinin activator. Rapid infusion of albumin may lead to extremely high plasma concentrations of bradykinin if ACE is inhibited. Stopping treatment with ACEIs 24 hours before plasma exchange prevents this adverse response.
In these cases, all three patients were taking angiotensin-converting enzyme inhibitors and developed profound hypotensive reactions, with a possible link to the infusion of Gelofusin. We suggest that these reactions occurred because of raised plasma kinin levels associated with inhibition of ACE. The source of kinins may be endogenous or exogenous. Genetic differences, or variable effectiveness of ACE inhibition, may explain why not all patients taking inhibitors preoperatively develop the severe reactions reported here.
We suggest that until results of further studies are available, ACEIs should be stopped 24 hours before surgery. These cases have been reported to the Committee for the Safety of Medicines (U.K.).
